On 6/29/22, the HOPE for Harvey Foundation signed a contract with Everlum Bio, a rare disease lab who believes that everyone deserves a cure, no matter how big or small the disease. Everlum Bio is based in Austin, TX, and we are excited to partner with them on creating a treatment for DLG4-related Synaptopathy, focusing on ASOs and small molecule screening. Through this relationship and in collaboration with iXcells, HOPE for Harvey successfully derived 6 induced pluripotent stem cell (iPSC) lines for DLG4 and designed some potential ASO candidates. Due to limited binding potential at this time for Harvey's specific binding locations for ASOs, we are currently reaching out to nonprofits like n-Lorem, so we complete more research to better understand the impacts of Harvey's specific mutation and differences from other DLG4 mutations.
On 3/16/23, HOPE for Harvey signed an additional contract with Hebrew University of Jerusalem and Rami Aqeilan's lab in collaboration with the SHINE Foundation to support the research and development of a virus-based gene replacement therapy called an AAV. Dr. Aqeilan's lab has successfully identified an AAV and has developed neuronal lines and brain organiods (3D neurons) of various DLG4 mutations. Dr. Aqeilan's lab has shown that introducing a good copy of DLG4 does appear to improve symptoms in mutated lines, including Harvey's. They are now working on grant and commercial funding to continue testing their AAV for DLG4.
In the summer of 2023, the HOPE for Harvey Foundation applied for two DLG4 animal model grants at Jackson Laboratories (Jax) and the Center for Precision Animal Modeling (C-PAM) at the University of Alabama at Birmingham (UAB), and both were accepted and are currently in progress. After a failed attempt in December 2023, Jax re-engineered their mouse model carrying Harvey's specific missense mutation, and had their first pups born in May 2024. Jax was able to identify male mice carrying the transgene and was able to successfully breed those mice in July 2025. Jax is continuing to breed these mice and identify treatable symptoms. We hope to be ready to send these mice out to labs to test various gene therapy approaches in the coming months.
In the spring of 2024, HOPE for Harvey began working with NeuCyte on generating iNeurons from the iPSC cell lines in order to test treatments and better understand how different variants function, including Harvey's mutation. Using multi-electrode arrays (MEAs), NeuCyte observed differences between the mutated and healthy neurons. In addition, NeuCyte has run RNAsequencing on Harvey's mutant neurons compared to healthy neurons and has identified differences in related proteins and impacted pathways, which could be treated with readily available drugs. Harvey's family has begun exploring those drug candidates. We hope to use AI technology to narrow our target list from all of the potential targets identified. One we have all of the neuronal lines, NeuCyte has run several tests, including more MEA data and various assays such as SiRNA designs to look at what 'knocking down' the mutant copy would do to the mutant neurons compared to the healthy neurons, which does support that a potential ASO strategy could be beneficial for Harvey. HOPE for Harvey is continuing to explore this pathway by connecting with the n-Lorem Foundation.
In August 2025, HOPE for Harvey signed a contract with Grann Pharmaceuticals to develop a lipid nano particle (LNP), which will carry a healthy copy of DLG4 mRNA into the body through regular infusions in order to code more healthy DLG4 protein. Grann has successfully entered a recent clinical trial for Retts Syndrome using this strategy in record time. Due to the speed, safety profile, and efficacy so far, HOPE for Harvey has decided to primarily focus on this treatment pathway for the time being. Grann Pharmaceuticals has developed a one-stop shop and is currently supporting this rare disease research at cost, which allows small organizations like HOPE for Harvey the opportunity to create a therapeutic for rare diseases. Grann will assist HOPE for Harvey in the pre-clinical development and testing of the LNP mRNA in mice carrying Harvey's mutation while looking for improvements in mice symptoms, they will conduct safety/toxicology studies in those treated mice, they will assist HOPE for Harvey through the FDA application and approval for the LNP mRNA treatment, Grann will conduct the manufacturing of the LNP, and they will assist in coordinating/organizing the clinical trial and treatment protocol for HOPE for Harvey in collaboration with COMBINEDBrain. It is possible HOPE for Harvey will be entering clinical trials for this LNP mRNA in early 2027.
As of August 2025, we are currently working on these specific pre-clinical development tasks with funds from our GoFundMe/GiveButter Campaigns and HOPE for Harvey Foundation Fundraising Efforts with the following estimated costs:
Current Total Costs: ~$828,500 without the clinical trial costs to family
Currently need to raise ~$230,000 to finish these projects. If we can fundraise another $100,000 to help offset these costs, this is achieveable with additional familial donations, and a treatment for DLG4 is a real possibility.
HOPE for Harvey is currently exploring various grant opportunities as well to help offset these and future research expenses
Check-out this video from our AAV project with Rami Aqeilan, Hebrew University of Jerusalem
Currently there are no treatment options for DLG4-related Synaptopathy. We hope to change that with your help! 100% of donations will support the development of various treatment modalities.
Due to advocacy by HOPE for Harvey Foundation, four additional academic labs recently started research projects on DLG4-related Synaptopathy:
"Collins concluded by thanking his audience while urging them to do more. 'Of nearly 7,000 genetic disorders, only 500–600 have an FDA-approved therapy,' he said. The goal is to develop therapies for the thousands of disorders for which patients and their families are still waiting in vain."
"After excluding genetic variants that were also found in the control group and in a separate large cohort of more than 60,000 individuals without autism, Doan, Yu and colleagues were left with 41 genes that were knocked out only in individuals with autism. Overall, the researchers estimate that these genes explain another 3 to 5 percent of all cases of autism (2 percent from loss-of-function mutations, and 1 to 3 percent from missense mutations)."
Sign up to hear from us about updates on our research toward a treatment for DLG4!
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.